High T-helper-1 cytokines but low T-helper-3 cytokines, inflammatory cytokines and chemokines in children with high risk of developing type 1 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 6, 2007, Pages 462-471

  Stechova, Katerina ^a   Bohmova, Kristyna ^a   Vrabelova, Zuzana ^a   Sepa, Annelie ^b   Stadlerova, Gabriela ^a   Zacharovova, Klara ^a   Faresjö, Maria ^b  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Cytokines chemokines; High risk children; Protein micro array; T helper cells; Type 1 diabetes

Indexed keywords

C PEPTIDE; CHEMOKINE; CYTOKINE; GAMMA INTERFERON; GLUTAMATE DECARBOXYLASE 65; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; LYMPHOTOXIN; MITOGENIC AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOKINE UNREGULATED BY GAMMA INTERFERON; PANCREAS ISLET CELL ANTIBODY; PHYTOHEMAGGLUTININ; RANTES; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CELL STIMULATION; CHILD; CHILD HEALTH CARE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DIABETOGENESIS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GROWTH RELATED ONCOGENE; HELPER CELL; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; IMMUNOPATHOGENESIS; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE DIABETES MELLITUS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MICROARRAY; SUPERNATANT; TH1 CELL; TH3 CELL;

ADOLESCENT; BIOLOGICAL MARKERS; C-PEPTIDE; CHEMOKINES; CHILD; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION MEDIATORS; MALE; T-LYMPHOCYTES, REGULATORY; TH1 CELLS;

EID: 34948897493     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.718     Document Type: Article

References (48)

1. Castano L, Eisenbarth GS. Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 1990; 8: 647-679.
2. Atkinson MA, Kaufman DL, Campbell L, et al. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992; 339: 458-459.
3. Foulis AK, Farquharson MA, Meager A. Immunoreactive a-interferon in insulin-secreting b cells in type 1 diabetes mellitus. Lancet 1987; 2: 1423-1427.
4. Somoza N, Vargas F, Roura-Mir C, et al. Pancreas in recent onset insulin-dependent diabetes mellitus: Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor Vb usage, and cytokine profile. J Immunol 1994; 153: 1360-1377.
5. Huang X, Yuan J, Goddard A, et al. Interferon expression on the pancreases of patients with type I diabetes. Diabetes 1995; 44: 658-664.
6. Foulis AK, McGill M, Farquharson MA. Insulitis in type 1 (insulin-dependent) diabetes mellitus in man - macrophages, lymphocytes, and interferon-g containing cells. J Pathol 1991; 165: 97-103.
7. Hussain MJ, Peakman M, Gallati H, et al. Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 1996; 39: 60-69.
8. Kallmann BA, Hüther M, Tubes M, et al. Systemic bias of cytokine production toward cell-mediated immune regulation in IDDM and toward humoral immunity in Graves'disease. Diabetes 1997; 46: 237-243.
9. Kallan AA, Duinkerken G, de Jong R, et al. Th1-like cytokine production profile and individual specific alterations in TCRBV-gene usage of T cells from newly diagnosed type 1 diabetes patients after stimulation with b-cell antigens. J Autoimmun 1997; 10: 589-598.
10. Karlsson MGE, Sederholm Lawesson S, Ludvigsson J. Th1-like dominance in high-risk first-degree relatives of type 1 diabetic patients. Diabetologia 2000; 43: 742-749.
11. Karlsson Faresjö MGE, Ludvigsson J. Diminished Th1-like response to autoantigens in children with a high risk of developing type 1 diabetes. Scand J Immunol 2005; 61: 173-179.
12. Hedman M, Ludvigsson J, Karlsson Faresjö MGE. Nicotinamide reduces high secretion of IFN-g in high-risk relatives even though it does not prevent type 1 diabetes. J Interferon Cytokine Res 2006; 26: 207-213.
13. Halminen M, Simell O, Knip M, Ilonen J. Cytokine expression in unstimulated PBMC of children with type 1 diabetes and subjects positive for diabetes-associated antibodies. Scand J Immunol 2001; 53: 510-513.
14. Lohmnann T, Laue S, Nietzschmann U, et al. Reduced expression of Th1-associated chemokine receptors on peripheral blood lymphocytes at diagnosis of type 1 diabetes. Diabetes 2002; 51: 2474-2480.
15. Karlsson Faresjö M, Ernerudh E, Ludvigsson J. Cytokine profile in children during the first 3 months after the diagnosis of type 1 diabetes. Scand J Immunol 2004; 59: 517-526.
16. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TIM. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 2005; 54: 92-99.
17. Bradley LM, Asensio VC, Schioetz LK, et al. Islet-specific Th1, but not Th2, cells secrete multiple chemokines and promote rapid induction of autoimmune diabetes. J Immunol 1999; 162: 2511-2520.
18. Chen MC, Proost P, Gysemans C, Mathieu C, Eizirik DL. Monocyte chemoattractant protein-1 is expressed in pancreatic islets from prediabetic NOD mice and in interleukin-1 beta-exposed human and rat islet cells. Diabetologia 2001; 44: 325-332.
19. Cardozo AK, Proost P, Gysemans C, Chen MC, Mathieu C, Eizirik DL. IL-1b and IFN-g induce the expression of diverse chemokines and IL-15 in human and rat pancreatic islet cells, and in islets from pre-diabetic NOD mice. Diabetologia 2003; 46: 255-266.
20. Carvalho-Pinto C, Garcia MI, HGomez L, et al. Leukocyte attraction through the CCR 5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice. Eur J Immunol 2004; 34: 548-557.
21. Kirman I, Vainer B, Nielsen OH. Interleukin-15 and its role in chronic inflammatory diseases. Inflamm Res 1998; 47: 285-289.
22. Group E.N.D.I.S.E. European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trail of intervention before the onset of type 1 diabetes. Lancet 2004; 363: 925-931.
23. Karlsson MGE, Garcia J, Ludvigsson J. Cow's milk proteins cause similar Th1- and Th2-like immune response in diabetic and healthy children. Diabetologia 2001; 44: 1140-1147.
24. Stechova K, Kolouskova S, Sumnik Z, et al. Anti-GAD65 reactive peripheral blood mononuclear cells in the pathogenesis of cystic fibrosis diabetes mellitus. Autoimmunity 2005; 38: 319-323.
25. Schloot NC, Meierhoff G, Karlsson Faresjö M, et al. Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the Third Immunology of Diabetes Society T-cell Workshop. J Autoimmun 2003; 21: 365-376.
26. Wahlberg J, Fredriksson J, Vaarala O, Ludvigsson J, Group F.T.A.s. Vaccinations may induce diabetes-related autoantibodies in one-year-old children. Ann N Y Acad Sci 2003; 1005: 404-408.
27. Heding LG. Radioimmunological determination of human C-peptide in serum. Diabetologia 1975; 11: 541-548.
28. Karlsson Faresjö MGE, Vaarala O, Thuswaldner S, Ilonen J, Hinkkanen A, Ludvigsson J. Diminished IFN-gamma response in children with type 1 diabetes. Diabetes Metab Res Rev 2006; 22: 462-470.
29. Avanzini MA, Ciardelli L, Lenta E, et al. IFN-gamma low production capacity in type 1 diabetes mellitus patients at onset of disease. Exp Clin Endocrinol Diabetes 2005; 113: 313-317.
30. Kaufman DL, Clare-Salzler M, Tian J, et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366: 69-72.
31. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994; 94: 2125-2129.
32. Schloot NC, Roep BO, Wegmann DR, Yu L, Wang TB, Eisenbarth GS. T-cell reactivity to GAD65 peptide sequences shared with coxsackie virus protein in recent-onset IDDM, post-onset IDDM patients and control subjects. Diabetologia 1997; 40: 332-338.
33. Mayer AF, Rharbaoui C, Thivolet J, Orgiazzi J, Madec AM. The relationship between peripheral T cell reactivity to insulin, clinical remissions and cytokine production in type 1 (insulin-dependent) diabetes mellitus. J Endocrinol Metab 1999; 84: 2419-2424.
34. Kukreja A, Cost G, Marker J, et al. Multiple immuno-regulatory defects in type-1 diabetes. J Clin Invest 2002; 1: 131-140.
35. Hanifi-Maghaddam P, Schloot NC, Kappler S, Seissler J, Kolb H. An association of autoantibody status and serum cytokine levels in type 1 diabetes. Diabetes 2003; 52: 1137-1142.
36. Marfaing-Koka A, Devergne O, Gorgone G, et al. Regulation of the production of the RANTES chemokine by endothelial cells. J Immunol 1995; 154: 1870-1878.
37. Mlynarski WM, Placha GP, Wolkow PP, Bochenski JP, Warram JH, Krolewski AS. Risk of diabetic nephropathy in type 1 diabetes is associated with functional polymorphisms in RANTES receptor gene (CCR5). Diabetes 2005; 54: 3331-3335.
38. Boulassel MR, Smith GHR, Edwardes MD, et al. Influence of RANTES, SDF-1 and TGF-b levels on the value of interleukin-7 as a predictor of virological response in HIV-1-infected patients receiving double boosted protease inhibitor-based therapy. HIV Med 2005; 6: 268-277.
39. Kinter A, Catanzaro A, Monaco J. CC-chemokines enhance the replication of t-tropic strains of HIV-1 in CD4(+) T cells: Role of signal transduction. Proc Natl Acad Sci U S A 1998; 95: 11880-11885.
40. Gunn MD, Nelken NA, Liao X, Williams LT. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J Immunol 1997; 158: 376-383.
41. Piemonti L, Leone BE, Nano R. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002; 51: 55-65.
42. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood 2001; 97: 14-32.
43. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280: E745-E751.
44. Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 2005; 54: S114-S124.
45. Devaraj S, Glaser N, Griffen S, Wang-Polagruto J, Miguelino E, Jialal I. Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes 2006; 55: 774-779.
46. Bopegamage SA, Petrovicova A. Tumor necrosis factor alfa and glucose levels in sera of mice infected with coxscakie B4 and A7 viruses. Acta Virol 1998; 42: 409-411.
47. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor-alpha and insulin resistance in obese men with Type 2 diabetes mellitus. Diabetes Res Clin Pract 2001; 52: 119-123.
48. Halse R, Pearson SL, McCormack JG, Yeaman SJ, Taylor R. Effects of tumor necrosis factor-alpha on insulin action in cultured human muscle cells. Diabetes 2001; 50: 1102-1109.